Cyclacel Pharma (CYCC) Misses Q4 EPS by 45c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. GOOGL
2. NOW
3. MSFT
4. AMZN
5. FTNT
6. EBAY
7. INTC
8. TENB
9. BIIB
10. CMG

Go back to Cyclacel Pharma (CYCC) Misses Q4 EPS by 45c

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

March 28, 2017 4:05 PM EDT

BERKELEY HEIGHTS, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2016. The Company's net loss applicable to common shareholders for the three months and year ended December 31, 2016 was $2.9 million and $12.0 million, respectively. As of December 31, 2016, cash and cash... More